002653 Haisco Pharmaceutical Group
- 30.63
- -0.18-0.58%
Haisco Pharmaceutical Group News
HiCisco (002653.SZ): Schuning is expected to file an NDA in the US within the next year
GLONGHUI May 10 丨 HiCisco (002653.SZ) held a performance briefing on May 10, 2024 to discuss “How is the listing of Si Shuning progressing in the US, and when is it expected to go on sale?” The company replied that Si Shuning is expected to file an NDA in the US within the next year, and the exact time it will be approved for listing in the US cannot yet be accurately predicted.
HiCisco (002653.SZ): It is expected that the market share of cyclopofol will increase to about 15% this year
GLONGHUI May 10 丨 HiCisco (002653.SZ) held a performance briefing on May 10, 2024 to discuss “How much does the company expect its share of the cyclopofol market to increase this year? What are the main competitors facing in the market?” The company replied that it is expected that the market share of cyclopofol will increase to about 15% this year. The main competition it faces is propofol (containing medium to long chain) injections, dexmedetomidine hydrochloride injections, and etomidate injections.
HiCisco (002653.SZ): Sales target for 2024 is approximately 17 million units
GLONGHUI May 10 丨 HiCisco (002653.SZ) held a performance briefing on May 10, 2024 to discuss “What is the sales target of Si Shuning for the whole year of this year?” The company replied that the sales target for Sishuning in 2024 is about 17 million units (this is only a sales target; it does not constitute a promise).
A-share midday announcement: Grimmie signs strategic cooperation agreement to jointly promote large-scale equipment upgrades and consumer goods trade-in
① Grimmie: The company and 21 partners including Shenzhen SF Integrated Logistics Service Co., Ltd., Guangzhou Shiyuan Electronic Technology Co., Ltd., Jingjin Equipment Co., Ltd., Suzhou Huichuan Technology Co., Ltd., Fangzheng Valve Group Co., Ltd., Shandong Tianli Energy Co., Ltd., Weiming Environmental Protection Equipment Group Co., Ltd., Emerson Process Control Co., Ltd. signed a strategic cooperation agreement on April 30 to jointly build a digital recycling platform, establish a reverse recycling logistics supply chain service system, and carry out equipment upgrade and remanufacturing. Next display and supply chain sales are big
HiCisco (002653.SZ) plans to terminate the Riluzole Oral Solution License Introduction Agreement and fully accrue asset impairment preparations
HiCisco (002653.SZ) announced the company's riluzole oral solution EXSERVAN project (abbreviation...
Southwest Securities released a research report on April 24 stating that it gave HiCisco (002653.SZ) a purchase rating. The main reasons for the rating include: 1) the domestic market share of cyclopofol is 11%, and it is expected that NDA will be declare
Southwest Securities released a research report on April 24 stating that it gave HiCisco (002653.SZ) a purchase rating. The main reasons for the rating include: 1) the domestic market share of cyclopofol is 11%, and it is expected that NDA will be declared in the US in 2024; 2) HSK16149 capsules are expected to be approved for marketing in 2024Q2; 3) the HSK21542 injection application has been accepted, and the oral dosage form has entered Phase II clinical trials; 4) the innovation pipeline is progressing rapidly, and potential varieties such as NASH and PROTAC are worth looking forward to. (Mainichi Keizai Shimbun)
Debon Securities released a research report on April 23 stating that it gave HiCisco (002653.SZ) a purchase rating. The main reasons for the rating include: 1) the performance was in line with expectations, and Q1 revenue increased 20% year over year; 2)
Debon Securities released a research report on April 23 stating that it gave HiCisco (002653.SZ) a purchase rating. The main reasons for the rating include: 1) the performance was in line with expectations, and Q1 revenue increased 20% year over year; 2) the domestic release of cyclopofol was rapid, and internationalization progressed smoothly; 3) there are plenty of follow-up pipelines, and 12 Class 1 innovative drugs have entered the clinical stage, which ushered in the harvest period. (Mainichi Keizai Shimbun)
HiCisco (002653): The differentiated innovative layout has entered the harvest period, and the pipeline is rich and has great potential
Results were in line with expectations, with Q1 revenue up 20% year over year. Revenue in 2023 was $3.355 billion, 11.27% YoY. Net profit attributable to mother was 295 million yuan, 6.51% year-on-year. Non-net profit withheld from mother $242 million
HiCisco (002653): Performance is in line with expectations, new product launches are progressing steadily
Incident Overview Recently, the company released the 2023 Annual Report & 2024 Quarterly Report. The 2023 revenue was 3.355 billion yuan (+11.3%), net profit due to mother was 295 million yuan (+6.5%), net profit not returned to mother
HiCisco (002653): HSK16149 approved, can be expected to go overseas
Incident: The company released the 2023 annual report and the 2024 quarterly report, achieving operating income of $3.355 billion (+11.27%) and net profit attributable to shareholders of listed companies of $295 million (+6.51%), and ownership
HiCisco (002653.SZ): Net profit of 91.9559 million yuan in the first quarter increased 219.86% year over year
On April 19, GLONGHUI (002653.SZ) released its first quarter report. Operating revenue was 752 million yuan, up 20.60% year on year, net profit of 91.9559 million yuan, up 219.86% year on year, after deducting non-net profit of 29.74 million yuan, up 4.37% year on year, with basic earnings of 0.08 yuan per share.
Haisco Pharmaceutical Gets Nod to Trial HSK16149 Capsules
Haisco Pharmaceutical Group (SHE:002653) will hold clinical trials on the HSK16149 capsules after getting the approval of China's National Medical Products Administration, according to the company's d
HiCisco (002653.SZ): HSK16149 capsule clinical trial approved
HiCisco (002653.SZ) issued an announcement. The company recently received “Drugs...” issued by the State Drug Administration
Express News | HiCisco: Received a notice of approval for clinical trials of the innovative drug HSK31858 tablets for new indications
Haisco Pharma Gets Nod to Trial Asthma Drug
China's National Medical Products Administration approved Haisco Pharmaceutical Group's (SHE:002653) application to conduct clinical trials on the HSK31858 tablet, the company said in its filing on th
Express News | HiCisco: Received the “Drug Clinical Trial Approval Notice” for the new indication of the innovative drug HSK31858 tablets
Haisco Pharma Gets Nod to Trial HSK16149 Capsule as Central Neuropathic Pain Drug
Haisco Pharmaceutical Group (SHE:002653) will hold a clinical trial on the HSK16149 capsule after receiving approval from China's National Medical Products Administration, according to the company's d
HiCisco (002653.SZ): Received 69.3619 million yuan in industrial development support funds
Gelonghui, March 31, 丨 HiCisco (002653.SZ) announced that the company and its subsidiary Tibet Haize Marketing Management Co., Ltd. (“Tibet Haize”) received a total of 69.3619 million yuan in industrial development support funds disbursed by the Tibet Shannan Happy Home Construction Administration on March 29, 2024. The above funds have already been paid. The industrial development support funds received this time are related to the company's daily business activities and are not sustainable.
Express News | HiCisco: Obtaining an Approval Notice for Clinical Trials of HSK16149 Capsules for New Indications
Express News | HiCisco: IND application for innovative drug HSK42360 tablets “Notice of Acceptance”
Analysis
Price Target
No Data
